Literature DB >> 11376466

The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease.

C Ballard1, J O'Brien, C M Morris, R Barber, A Swann, D Neill, I McKeith.   

Abstract

BACKGROUND: Little is known about the rate of progression or associations of cognitive impairment in dementia with Lewy bodies (DLB), or the associations of accelerated decline.
METHOD: Dementia patients from a case register were evaluated at baseline and 1 year follow-up using the Cambridge Assessment for Mental Disorders in the Elderly, section B (CAMCOG) and the Mini-Mental State Examination (MMSE) to determine the rate of cognitive decline. Operationalized clinical diagnoses were applied (NINCDS ADRDA for Alzheimer's disease (AD), NINCDS AIRENS for vascular dementia (VaD) and consensus criteria for DLB).
RESULTS: One hundred and ninety-three patients completed annual MMSE schedules (AD, 101; DLB, 64; VaD, 38), of whom 154 completed the CAMCOG. The magnitude of cognitive decline (MMSE, 4-5 points; CAMCOG, 12-14 points) was similar in each of the dementias. The strongest predictor of accelerated cognitive decline in DLB was the apolipoprotein E4 allele (17.5 vs 8.3 points decline on the CAMCOG).
CONCLUSION: Over 1 year, DLB, VaD and AD patients had similar rates of cognitive decline overall. Apolipoprotein E4 may be an important predictor of more rapid decline in DLB. Copyright 2001 John Wiley & Sons, Ltd

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11376466     DOI: 10.1002/gps.381

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  16 in total

1.  Risk of decline in functional activities in dementia with Lewy bodies and Alzheimer disease.

Authors:  Dawn P Gill; Thomas D Koepsell; Rebecca A Hubbard; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Jan-Mar       Impact factor: 2.703

2.  Cognitive performance after first ever stroke related to progression of vascular brain damage: a 2 year follow up CT scan study.

Authors:  S M C Rasquin; F R J Verhey; R Lousberg; J Lodder
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

3.  Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies.

Authors:  D J Burn; E N Rowan; L M Allan; S Molloy; J T O'Brien; I G McKeith
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05       Impact factor: 10.154

4.  Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.

Authors:  J A Schneider; Z Arvanitakis; L Yu; P A Boyle; S E Leurgans; D A Bennett
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

5.  Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions.

Authors:  Josef Marksteiner; Reinhold Schmidt
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 6.  Dementia with Lewy bodies.

Authors:  Tanis J Ferman; Bradley F Boeve
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

7.  Predicting aggressive decline in mild cognitive impairment: the importance of white matter hyperintensities.

Authors:  Giuseppe Tosto; Molly E Zimmerman; Owen T Carmichael; Adam M Brickman
Journal:  JAMA Neurol       Date:  2014-07-01       Impact factor: 18.302

8.  Dementia with Lewy bodies.

Authors:  Ian McKeith
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

9.  The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia.

Authors:  Kajsa Stubendorff; Dag Aarsland; Lennart Minthon; Elisabet Londos
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

10.  Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps.

Authors:  Shien Guo; Denis Getsios; Luis Hernandez; Kelly Cho; Elizabeth Lawler; Arman Altincatal; Stephan Lanes; Michael Blankenburg
Journal:  Int J Alzheimers Dis       Date:  2012-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.